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NH2   Amino 
NP   Nucleoprotein 
NS   Non-structural 
-OH   Hydroxyl group 
P   Product 
PA   Polymerase acidic protein 
PB   Polymerase basic protein 
PBS   Phosphate buffered saline 
PDB   Protein data bank 
P-gp   P-glycoprotein 
pKa   Acid dissociation constant 
PMV   Phyton Molecular Viewer 
QSAR   Quantitative Structure Activity Relationship 
RdRp   RNA-dependent RNA polymerase 
RNA   Ribonucleic acid 
S   Substrate  
SA   Sialic acid 
Ser   Serine 
-SH   sulfohydryl group 
Trp   Triptophan 
Tyr   Tyrosine 
UDP   Uridine5'-diphospho-glucuronosyltransferase (UDP- 
   glucuronosyltransferase  
UGT   Uridine 5'-diphospho-glucuronosyltransferase 
Vmax   Maximum velocity 
Vo   Initial velocity 
vRNP   Viral ribonucleoprotein 
WHO   World Health Organization 
α   alpha 
β   beta 
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PERENCAT NEURAMINIDASE BERPOTENSI MELALUI SARINGAN 
MAYA, KAJIAN KINETIK, DAN JANGKAAN ADME 
ABSTRAK 
Aktiviti neuraminidase (NA) memainkan peranan yang penting dalam 
jangkitan oleh virus influenza dengan memudahkan pelepasan virion yang baru 
ditubuhkan daripada reseptor sel tuan rumah dan menggalakkan jangkitan kepada sel-
sel atau organ-organ lain. Disebabkan kemunculan rintangan virus terhadap perencat 
NA sedia ada, penemuan perencat NA baru amat diperlukan. Dalam kajian ini, 
pemeriksaan maya berdasarkan pendokan sebatian-sebatian daripada pangkalan data 
NCI untuk memilih dengan pantas hit in silico bagi menjadi potensi perencat NA telah 
dijalankan. Satu kaedah in vitro baru telah dicuba untuk membangunkan perencatan 
asai NA dengan menggunakan teknologi AlphaScreenTM dengan Alpha-1-Asid 
Glikoprotein sebagai substrat. Malangnya, usaha ini tidak berjaya mungkin disebabkan 
pemisahan tidak spesifik asid sialik oleh NA. Selepas itu, asai MUNANA tradisional 
telah dijalankan untuk menyiasat aktiviti perencatan dan parameter kinetik sebatian 
perencat. Akhir sekali, sebatian-sebatian terpilih dikaji untuk ciri farmakokinetik in 
silico mereka. Dari pangkalan data NCI, 1541 sebatian telah berjaya disaring untuk 
mendapatkan 40 kompaun hit in silico diikuti oleh asai MUNANA untuk menentukan 
IC50 mereka. Sepuluh daripada mereka menunjukkan lebih daripada 50% perencatan 
terhadap NA dan empat sebatian iaitu NSC 5069, NSC 83318, NSC 156563, dan NSC 
134137 didapati mempunyai nilai IC50 sebanyak  masing-masing 216 μM, 320 μM, 
571 μM dan 673 μM. Kajian kinetik menunjukkan nilai Km untuk MUNANA ialah 
36.44 μM dan Vmax bagi tindak balas enzim ialah 551.25 RFU / min. Daripada plot 
Dixon, semua sebatian mempunyai daya saing dengan nilai Ki untuk NSC 5069, NSC 
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83318, NSC 156563 dan NSC 134137 masing-masing ialah 100.26 μM, 204.13 μM, 
202.9 μM, 197.75 μM. Penilaian ciri-ciri kesamaan-dadah meramalkan sifat-sifat 
fizikokimia seperti berat molekul, Log P, bilangan ikatan hidrogen penderma dan 
penerima memenuhi Peraturan Lima Lipinski. Hasil nilai pKa menunjukkan bahawa 
sebatian berasid lemah dan cenderung untuk diserap dalam usus (NSC 5069 dengan 
nilai pKa 4.1, dan NSC 83318 dengan nilai pKa 6.3), dan kompaun berasid lebih kuat 
untuk diserap dalam perut (NSC 156563 dan NSC 134137 dengan nilai pKa 2.7). 
Pengiraan in silico TPSA menunjukkan bahawa NSC 83318 dan NSC 156563 
memenuhi kriteria Lipinski dengan mempunyai nilai TPSA kurang daripada 140 A2, 
manakala NSC 5069 dan NSC 134137 telah diramalkan untuk mempunyai penyerapan 
lemah kerana nilai TPSA mereka adalah lebih daripada had yang boleh diterima 140 
A2. Berdasarkan peratusan fraksi diserap, NSC 5069 dan NSC 83318 telah dianggap 
mempunyai fraksi tinggi untuk penyerapan. Manakala dua sebatian, NSC 156563 dan 
NSC 134137 telah mempunyai fraksi rendah untuk penyerapan. Dalam meramalkan 
isipadu pengedaran, hasil menunjukkan bahawa isipadu pengedaran NSC 5069, NSC 
83318, NSC 156563, NSC 134137 masing-masing adalah 0.86 L/kg, 0.7 L/kg, 0.13 
L/kg dan 0.12 L/kg. NSC 83318, NSC 156563, dan NSC 134137 mempunyai %PPB 
lebih daripada 90% yang bermakna bahawa hampir semua sebatian ditadbir boleh 
terikat kepada protein plasma dalam badan, manakala NSC 5069 mempunyai %PPB 
57%, menunjukkan bahawa 57% daripada kompaun adalah terikat kepada protein 
plasma. Akhir sekali, empat sebatian utama tidak menunjukkan kebarangkalian 
sebagai substrat atau perencat bagi kebanyakan isoform CYP, kecuali NSC 83318 
yang menunjukkan kebarangkalian yang tinggi untuk bertindak sebagai CYP 1A2 
dengan nilai 0.84. 
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POTENTIAL NEURAMINIDASE INHIBITORS VIA VIRTUAL 
SCREENING, KINETIC STUDIES, AND ADME PREDICTIONS 
ABSTRACT 
Neuraminidase (NA) activity plays an important role in the infection by 
influenza viruses by facilitating the release of the newly formed virions from the host 
cell receptor and promotes its infection to other cells or organs. With the emergence 
of viral resistance towards the existing NA inhibitors, the discovery of new NA 
inhibitors is urgently needed. In this work, docking-based virtual screening of large 
compounds from NCI database to rapidly select in silico hits to be potential NA 
inhibitors was carried out. A new in vitro method has been attempted to be developed 
for NA inhibition assay by utilizing AlphaScreenTM technology with Alpha-1-Acid 
glycoprotein as a substrate. Unfortunately, this effort was unsuccessful probably due 
to the non-specific cleavage of sialic acid by NA. Subsequently, a traditional 
MUNANA assay was performed to investigate the inhibitory activities and kinetic 
parameters of the inhibitor compounds. Finally, the selected compounds were studied 
for their pharmacokinetic properties in silico. From the NCI database, 1541 
compounds have been successfully screened and 40 in silico hits compounds were 
obtained, and assayed to determine their IC50s. Ten of them demonstrated over 50% 
inhibition against NA and four compounds namely NSC 5069, NSC 83318, NSC 
156563, and NSC 134137 were found having IC50 values of 216 µM, 320 µM, 571 µM 
and 673 µM, respectively. The kinetic studies showed Km value for MUNANA was 
36.44 µM and Vmax for the enzymatic reaction was 551.25 RFU/min. From the Dixon 
plot, these four compounds appeared to competitively inhibit the neuraminidase with 
Ki values for NSC 5069, NSC 83318, NSC 156563, and NSC 134137 were 100.26, 
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204.13, 202.90, and 197.75 µM, respectively. Drug-likeness properties assessment 
predicting the physicochemical properties such as molecular weight, Log P, number 
of hydrogen bond donor and acceptor fulfilled Lipinski's Rule of Five. The results of 
pKa value showed that the compounds are weakly acidic and tend to be absorbed in 
the intestine (NSC 5069 with pKa value 4.1, NSC 83318 with pKa value 6.3 and), and 
stonger acidic compound to be absorbed in the gastrik (NSC 156563 and NSC 134137 
with pKa value 2.7). In silico calculations of TPSA showed that NSC 83318 and NSC 
156563 fulfill Lipinski's criteria of having TPSA value less than 140 Å2, while NSC 
5069 and NSC 134137 were predicted to have poor permeation since their TPSA 
values are more than the acceptable upper limit of 140 Å2. Based on the fraction’s 
absorbed percentage, NSC 5069 and NSC 83318 were considered to have high fraction 
for the absorption. While the other two compounds, NSC 156563 and NSC 134137 
had low fraction for the absorption. In predicting volume distribution, the results 
showed that the volume distribution of NSC 5069, NSC 83318, NSC 156563, NSC 
134137 were 0.86 L/kg, 0.7 L/kg, 0.13 L/kg and 0.12 L/kg, respectively. NSC 83318, 
NSC 156563, and NSC 134137 have %PPB more than 90% which means that almost 
all the compounds administered may be bound to the plasma protein in the body, 
whereas NSC 5069 has %PPB 57%, indicating that 57% of the compound is bound to 
the plasma proteins. Lastly, the four top compounds showed no probability as 
substrates or inhibitors for almost all CYP isoforms, except for NSC 83318 which 
showed relatively high probability to act on CYP 1A2 with value 0.84. 
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CHAPTER ONE 
INTRODUCTION 
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 Influenza, according to WHO (World Health Organization), spreads around the 
world in seasonal epidemics, resulting the death between 250,000 and 500,000 people 
every year (Knobler et al., 2005). The three influenza pandemics that occurred in the 
20th century and killed tens of millions people were Spanish flu in 1918, Asian flu in 
1957, and then followed by Hong Kong flu in 1968-69. In the 21st century, the 
emergence of a highly pathogenic avian influenza virus of type A (H5N1) or bird flu, 
the pandemic of 2009 H1N1 (Swine flu), and also a recent case of a new avian 
influenza A (H7N9), which was firstly reported in China in March 2013, have led this 
disease becoming a threatening health issue in human (Hu et al., 2014). 
 Centers for Disease Control and Prevention (CDC) study of the disease burden 
of 2009 H1N1 pandemic, showed that the largest death burden took place in the 
African and Southeast Asian regions, with more than half of 2009 H1N1-related deaths 
occurred (Dawood et al., 2012). Since the first reported case in May 2009, Malaysia 
has witnessed 2,253 cases of H1N1 infection as of August 2009. The number of cases 
had been increasing and as of September 2009, there have been 73 death reported 
(Kementerian Kesihatan Malaysia, 2011). 
 Vaccination has become a primary strategy for the prevention of influenza. 
However in 2005, in some cases vaccination were inadequate, especially during the 
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course of pandemic. Current vaccine production methods cannot be carried out with 
the speed required to halt the development of new strains of influenza virus; therefore, 
it is possible that vaccine may not be available for the first wave of the virus outbreak. 
The limitations of vaccine efficacy, design and delay in strain specific vaccine 
production have stimulated the search for antivirals. Thus, antiviral agents form an 
important part of a rational approach to overcome epidemic influenza (Moscona, 2005, 
Boltz et al., 2010). Two classes of antivirals are currently approved for both 
prophylaxis and therapeutic treatment of influenza virus infection: M2-ion channel 
inhibitors (the adamantanes, amantadine and its derivative, rimantadine) and 
neuraminidase inhibitors (zanamivir and oseltamivir). Neuraminidase inhibitors have 
better tolerance, broader antiviral spectrum, and less potential for the emergence of 
resistance compared to the M2 inhibitor (Gubareva et al., 2000). Neuraminidase 
inhibitors are also currently the preferred treatment option for flu virus infection since 
they are less toxic and more effective (Beigel and Bray, 2008). Zanamivir and 
oseltamivir are examples of neuraminidase inhibitors, which are already licensed and 
commercially available for the treatment and prophylaxis of influenza. However, the 
poor oral bioavailability of zanamivir requires this drug to be administered by 
inhalation, while oseltamivir-resistant H1N1 viruses have emerged due to the latter 
broad use as oral medication. Recently, laninamivir, a potent neuraminidase inhibitor 
has been approved for use in Japan. Unfortunately, its effectiveness against 
oseltamivir-resistant neuraminidase in adults has not been proven, thus more study is 
needed to find new and more effective anti-influenza agents (Ives et al., 2002, 
Vavricka et al., 2011). 
 Currently, the activity of neuraminidase inhibitor is determined using a 
fluorogenic assay utilizing 2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid 
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(MUNANA) as substrate. This method is quite sensitive and has been the most widely 
used and accepted method for detecting neuraminidase inhibition activity. However, 
typically in screening large libraries of chemicals, this assay is not very economical. 
A lot of enzymes are needed to conduct the experiments. Thus, fast, robust, sensitive, 
and reliable assays are needed. Therefore, the ultimate aim of this research is to 
develop an alternative neuraminidase inhibition assay, as well as to test this assay, to 
validate the inhibition of potential neuraminidase inhibitor from NCI database. 
The present study focused on the development of neuraminidase inhibition 
assay using AlphaScreenTM technology to screen potential neuraminidase inhibitors. 
Following the optimization of the assay, it was intended that the assay was to be 
validated by testing known inhibitors for their inhibition. Since the assay is high 
throughput, molecular docking and virtual screening of compounds from National 
Cancer Institute (NCI) Diversity Set II database were also employed to obtain top in 
silico hits compounds for subsequent alpha screen inhibition assay. However, due to 
the failure of establishment of the assay, a traditional MUNANA in vitro assay was 
performed to investigate these compounds’ inhibitory activities and their kinetic 
parameters. Finally the selected active compounds were studied for their 
pharmacokinetic properties in silico in an attempt to rationale their selection for further 
lead optimization, and possible drug development.  
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Specifically, the objectives of the study are to: 
1. Virtually screen National Cancer Institute Diversity Set II compounds for 
potential neuraminidase inhibitors using molecular docking methods; 
2. Screen these in silico hits compounds with in vitro fluorescence based assay 
with 2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) as 
substrate; 
3. Determine Vmax, Km for MUNANA substrate and Ki for the top compounds; 
4. Predict the ADME properties of the top compounds screened with 
ACD/ADME Suite software. 
1.2  The Influenza 
1.2.1 Epidemics and Pandemics 
 Influenza is a serious infectious disease that affects respiratory tract and can 
lead to hospitalization and even death. Annual epidemic of influenza is estimated to 
be 3 to 5 million cases of severe illnesses and ~500,000 deaths globally. The high-risk 
groups of severe consequences and death include persons aged 65 years and above, 
children under 2 years, and persons with chronic medical conditions that put them at 
increased risk of developing influenza or its complications (Fauci, 2006, WHO, 2014).  
 Novel strains of Influenza A virus emerge sporadically every 1 to 2 years as 
influenza epidemics. The introduction of selected point mutations within 
hemagglutinin (HA) and neuraminidase (NA), the two surface glycoproteins of 
influenza virus, evade the human host defenses and therefore resulting in no lasting 
immunity against the virus, neither after natural infection nor vaccination. The small 
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changes of antigenicity of influenza virus are termed antigenic drift and become the 
basis for regular occurrence of the epidemic of influenza (Holmes et al., 2005).  
 On the other hand, influenza pandemics which involve a major change in the 
antigenicity of influenza A virus occur once every 10 to 50 years. At least three 
influenza pandemics have been recorded during the twentieth century: the Spanish flu 
in 1918-19, Asian Flu in 1957 and Hong Kong Flu in 1968 with mortality impact 
ranged from devastating to mild (Holmes et al., 2005, Lazzari and Stöhr, 2004, Oxford, 
2000, Simonson, 2004). These viruses acquire a new subtype by re-assortment of RNA 
segments from different influenza viral strains. This genetic change, called antigenic 
shift, allows a viral strain to jump from one species of animal to another, including 
from animals to human (Figure 1.1) (Holmes et al., 2005, Wit and Fouchier, 2008). 
 
Figure 1.1 Influenza virus can change in two different ways. Antigenic drift is small 
changes in the virus that produces new virus strains. This may not be recognized by 
the body's immune system while antigenic shift is an abrupt, major change resulting 
new hemagglutinin and/or new hemagglutinin and neuraminidase proteins in influenza 
viruses. 
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The 1918 influenza pandemic, also referred to as Spanish Flu, was the first and 
the most devastating influenza pandemic in the 20th century. The pandemic spread 
globally by infecting 25-30% of the world's population and killing more than 50 
million people (Taubenberger and Morens, 2006). Analysis of 1918 flu survivors 
suggested that 1918 pandemic was caused by H1N1-subtype influenza virus that 
contained genes derived from avian-like virus, which was also believed as the common 
ancestor of almost all influenza A cases, including re-assorted H3N2 and H2N2 viruses 
and drifted H1N1 viruses (Taubenberger et al., 2000, Taubenberger and Morens, 2006). 
These virus strains continued to circulate until they were replaced by H2N2 in 1957 
influenza pandemic (Basler and Aguilar, 2008, Taubenberger and Morens, 2006). The 
influenza A virus with H2 subtype emerged in February 1957 in Hunan Province of 
China, considered clinically milder than 1918 pandemic virus with global mortality 
rate at 1-2 million deaths. The H2N2 virus circulated worldwide until H3N2 virus 
appeared in 1968 and replaced it. The 1968 influenza pandemic, also known as Hong 
Kong flu, was comparatively a milder pandemic with the death toll associated with it 
has been estimated around 1 million deaths (Oxford, 2000, Subbarao and Katz, 2000). 
The first influenza pandemic in 21st century began in 2009 when a new swine-origin 
influenza virus emerged and replaced the previous seasonal influenza H1N1. First 
identified in Mexico, the virus had spread to over 43 countries (Guarnaccia et al., 2013). 
The virus, often called "2009 H1N1", has been circulating in human and caused the 
first influenza pandemic in more than 40 years (CDC, 2014). Influenza A virus subtype 
H5N1, also called avian influenza or bird flu, is known to be highly pathogenic avian 
influenza A virus which caused devastating outbreaks in domestic poultry and give 
rise to the threat of human influenza pandemics. In July 2013 the WHO announced 
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630 confirmed human cases for avian influenza A (H5N1) in total which resulted in 
the deaths of 375 people since 2003 (WHO, 2013). 
1.2.2 The Influenza Virus 
 Influenza virus is an enveloped virus which belongs to the family of 
Orthomyxoviridae with negative-sense, single stranded, and segmented RNA genome. 
The virus is classified into three serologically different types, influenza virus A, B, and 
C, with type A is the most virulence which cause severe and even fatal respiratory 
disease, influenza epidemic and also worldwide pandemic (Itzstein and Thomson, 
2009, Gong et al., 2007, Nicholls et al., 2007, Samji, 2009). The influenza A viruses 
have eight segments which encode 11 viral genes: hemagglutinin (HA), neuraminidase 
(NA), matrix proteins M1 and M2, nucleoprotein (NP), non-structural (NS) proteins 
NS1 and NS2, polymerase acidic protein (PA), polymerase basic (PB) proteins PB1, 
PB2, and PB1-F2 (Samji, 2009). Influenza A viruses are further sub-divided based on 
the antigenic properties of their surface glycoproteins, HA and NA (Itzstein and 
Thomson, 2009, Gong et al., 2007). There are 18 known hemagglutinin subtypes and 
11 known neuraminidase subtypes (CDC, 2014, Tong et al., 2013). A simple diagram 
of influenza A virus is shown on Figure 1.2. Hemagglutinin is the major surface protein 
of influenza A virus which consists of three identical subunits (homotrimeric) 
anchored to the lipid membrane of the virus. It is responsible for the initial contact 
between the virus and the target cell which contains terminal N-acetylneuraminic acid 
(sialic acid) residues. Moreover, hemagglutinin also contributes to the internalisation 
of the virus through fusion of the viral envelope with the target cell (Itzstein and 
Thomson, 2009). Influenza virus neuraminidase is a tetrametric protein and acts as 
glycohydrolase which removes N-acetylneuraminic acid (sialic acid) residues from 
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glycoconjugates in the surface of target cells, a crucial role in facilitating the release 
of newly synthesized virus from the host cells (Itzstein and Thomson, 2009, Xu et al., 
2008).  
 
Figure 1.2 Diagram of influenza A virus. On the outside virus particles, 3 viral proteins: 
haemagglutinin (HA, trimers), neuraminidase (NA) (tetramers) and M2 (tetramers that 
make up ion-channels) are exposed (Hedestam et al., 2008). 
 
1.2.3 Influenza Virus Life Cycle 
 The life cycle of influenza virus can be divided into several stages: virus entry 
to the host cell; entry of vRNPs into the nucleus; transcription and replication of the 
viral genome; export of vRNPs from the nucleus; then assembly and budding at the 
host cell plasma membrane. The first stage of virus infection is the binding of HA to 
sialic acid found in the surface of host cell's membrane. Sialic acids are bound to 
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carbohydrates of the membrane's glycoprotein with glycosidic linkage. There are two 
major linkages that are important for the specificity of HA, α (2, 3) linkage which is 
recognized by viral HA from avians and equines, whereas those from human recognize 
α (2, 6) linkage and those from swine recognize both. Upon binding with sialic acids, 
receptor-mediated endocytosis occurs and the virus enters the host cell in an endosome. 
The low pH of endosome (around 5 to 6) triggers the fusion of the viral and endosomal 
membrane. The acidic endosomes also open up the M2 ion channel and acidifies the 
viral core. This acidic environment in the virion allows vRNP to be released from M1 
so that it is free to enter the host cell's cytoplasm as well as the nucleus. The viral 
proteins that make up the vRNP (NP, PA, PB1 and PB2) have recognized the nuclear 
localization signals (NLSs) which can bind to the cellular nuclear import machinery 
and thus, enter the nucleus to undergo transcription and replication. In order to be 
transcribed, the negative-sense RNA genome is first converted into a positive sense 
RNA as a template for the production of viral RNAs. The viral RHA dependent RNA 
polymerase (RdRp) initiates the synthesis of RNA internally in viral RNA, continued 
by cellular RNA Polymerase II (Pol II) that binds to DNA and starts transcription. 
vRNPs is then exported out from the nucleus through the nuclear pores. Before leaving 
the cell, virus needs to form viral particles. Therefore, the viral proteins that normally 
found within the viral lipid bilayer, i.e HA, NA, and M2, must be present and 
transported to the apical plasma membrane, since the virus particles bud from the 
apical side of polarized cells. After viral particles are formed, the sialic acid residues 
from glycoproteins and glycolipids are cleaved by neuraminidase, thus enable the viral 
particles to be released from the plasma membrane and goes on to infect neighboring 
cells (Samji, 2009). The virus life cycle is presented in Figure 1.3. 
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Figure 1.3 Influenza virus replication cycle (Gubareva et al., 2000). 
 
1.2.4 Influenza Virus Neuraminidase 
1.2.4.1 Structure of Neuraminidase 
 Influenza virus neuraminidase (EC 3.2.1.18) is a tetramer with four identical 
polypeptides composed of a cytoplasmic tail, a transmembrane domain, a globular 
head, and a stalk region (Gubareva et al., 2000, Gong et al., 2007). It destroys the 
receptors recognized by hemagglutinin by catalyzing the cleavage of terminal α-(2,3 
or 2,6)-ketosidically linked sialic acid (N-acetylneuraminic acid) from a wide range of 
glycoconjugates, including glycoproteins and glycolipids, thus playing an important 
role in the life cycle of the virus (Gubareva et al., 2000, Itzstein and Thomson, 2009). 
Neuraminidase acts as a biological scissor that cut sialic acids residues both from upper 
respiratory tract mucins facilitating the movement of the virus, and also from the 
surface of glycoprotein of the newly synthesized virions, thus enabling the virus to be 
released from the host cell and continue to infect other cells (Itzstein and Thomson, 
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2009). The first X-ray crystal structure of neuraminidase was published in 1983. In 
1992, Varghese and colleagues elucidated the structure of N2 subtype of 
neuraminidase at 2.9° Å resolutions as shown in Figure 1.4. The structure showed a 
tetrameric association of identical monomers with β-sheet propeller (Gong et al., 2007, 
Varghese et al., 1992).  
 
Figure 1.4 Three dimensional structure of an N2 neuraminidase tetramer in complex 
with sialic acids (PDB entry 2BAT) (Varghese et al., 1992). 
 The structural studies on NA enzymes from four influenza A viruses and two 
influenza B virus subtypes have discovered that NA structure is well conserved. 
Investigation conducted by Gong and colleagues on several NA structures showed that 
they have a generally similar topology to N2 NA (Gong et al., 2007). 
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1.2.4.2 The Substrate and the Active Site of Neuraminidase 
 Sialic acid (SA) is a generic term for nine-carbon sugar acids that are widely 
expressed on the surface of all cells in all animals of the deuterostome lineage 
(vertebrates and so-called "higher" invertebrates) and also in certain pathogenic or 
symbiotic bacteria that associate with them. It features conspicuously at terminal 
positions of the surface-exposed glycoconjugates (Severi et al., 2007, Suzuki et al., 
2000, Varki and Gagneux, 2012).  
 Sialic acid was first discovered about 70 years ago as a major product released 
by mild acid hydrolysis of brain glycolipids or salivary mucins by Gunnar Blix, Ernst 
Klenk, and other scientists (Du et al., 2009). Erwin Chargaff's group then found out 
that "receptor-destroying enzyme" of influenza viruses was able to release sialic acid 
from macromolecules and thus, acts as sialidase (Varki and Schauer, 2009). Karl 
Meyer's group observed a similar activity in bacteria, then the name "neuraminidase" 
was suggested for this activity by Alfred Gottschalk in 1957. Partially because of its 
discovery in salivary mucins (Greek: sialos), this family was named the "sialic acids" 
(Varki and Schauer, 2009).   
Sialic acids rarely occur freely in nature. They are more commonly found as 
components of oligosaccharide chains of mucins, glycoproteins, and glycolipids. They 
usually occupy terminal, non-reducing positions of oligosaccharide chains of complex 
carbohydrates on outer and inner membrane surfaces in various linkages, mainly to 
galactose, N-acetylgalactosamine, and other sialic acid moieties, where they are highly 
exposed and functionally important. Sialic acids consist of a family of 43 naturally 
occurring derivatives of the nine-carbon sugar neuraminic acid (5-amino-3, 5-dideoxy-
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D-glycero-D-galactononulsonic acid). One branch of the sialic acid family is N-
acetylated to form N-acetylneuraminic acids (Neu5Ac, NANA, Sia), which are the 
most widespread form of sialic acid and almost the only form found in human. The 
other branch is based on N-glycolylneuraminic acids (Neu5Gc) where the amino group 
is substituted with N-glycolyl group. These are found commonly in many animal 
species (best investigated in porcine tissues), but not found in humans except in the 
case of a particular cancer (Suzuki et al., 2000, Wang and Brand-Miller, 2003). Two 
most common forms of sialic acid are N-acetyl neuraminic acid (Neu5Ac) and N-
glycolylneuraminic acid (Neu5Gc) as shown in Figure 1.5. 
 
Figure 1.5 a. The two most common sialic acids are N-acetyl neuraminic acid (Neu5Ac) 
and N-glycolylneuraminic acid (Neu5Gc). b. Sialic acids are attached to carbohydrate 
chains on glycoproteins and glycolipids via different glycosidic linkages. The most 
common linkage types are α2, 3-linkage to a galactose residue, α2,6-linkage to a 
galactose moiety or to an N-acetylgalactosamine moiety, and α2,8-linkage to another 
sialic acid moiety on a glycan (Stencel-Baerenwald et al., 2014). 
 
 Neuraminidase is an exo-glycoside hydrolase that hydrolyzes terminal sialic 
acid residues from any glycoconjugate, including viral glycoprotein. In general, 
glycoside hydrolases (GH) are a group of enzyme which catalyze the hydrolysis of the 
glycosidic bond between two or more carbohydrates or between carbohydrates and 
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non-carbohydrates moiety. This group is classified in families based on amino acid 
sequence similarities. As of July 2015, CAZy (Carbohydrates-Active Enzyme) 
database describes the present knowledge of 133 glycoside hydrolase families. 
Neuraminidase, either from bacteria or viruses, belong to glycoside hydrolase family 
33, 34, 83 (Cantarel et al., 2009, Lombard et al., 2014). Hydrolysis of neuraminidase 
substrate was solvent-mediated and involved a sialosyl cation transition state 
intermediate. The pathway of neuraminidase consists of four major steps. The first step 
is the binding stage where the carboxylate group transforms from the axial position 
into a pseudo-equatorial position due to the charge-charge interactions to Arg 118, 
Arg292, and Arg371 and steric constraints with residue at the base of the active site, 
such as Tyr406. The following step involves proton donation from solvent and 
formation of the endocyclic sialocyl cation transition-state intermediate. The hydrogen 
bonding network of water molecules and protein residues leading from a charged 
group on the protein surface to water molecules could facilitate proton donation. Asp 
151 and Arg 152, and to a certain extent, for Glu 227, are believed to contribute to the 
stability of the cationic intermediate. The active site of neuraminidase with its 
important residues is presented in Figure 1.6. The final two steps are the formation and 
release of Neu5Ac. The expulsion of the product from the active site is favored by the 
mutarotation of the initial β-anomer to the more thermodynamically stable α-anomer 
for Neu5Ac in solution as shown in Scheme 1.1 (Gong et al., 2007).  
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Figure 1.6 Neuraminidase active site consists of functional amino acid residues 
Arg118, Asp151, Arg152, Arg224, Glu 276, Arg292, Arg371, and Tyr406, which are 
in direct contact with sialic acid, and structural amino acids residue Glu119, Arg156, 
Trp178, Ser179, Asp (or Asn in N7 and N9)198, Ile222, Glu227, Glu277, Asp293, and 
Glu42  (Protein Data Bank ID: 2BAT www.rcsb.org) (Varghese et al., 1992) . 
 
Scheme 1.1 Reaction steps and corresponding intermediates of catalytic pathway of 
neuraminidase (Gong et al., 2007). 
 
 
 
1 
2 
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1.2.4.3 Neuraminidase Inhibitor 
 The importance role of neuraminidase in the life cycle of influenza virus as 
well as the conversed nature of the neuraminidase active site among influenza viral 
strains have resulted the enzyme to be considered as an excellent target for antiviral 
drug design. Several approaches have led to the discovery of neuraminidase inhibitors 
through random screening or development and modifications of the functional groups 
of original substrate (Itzstein and Thomson, 2009). 
 Neuraminidase cleaves sialic acid residues on the host cell receptor to which 
the newly formed virion attached, enabling the virus to be released and invade the new 
host cells and continue the infections. Neuraminidase inhibitors mimic the natural 
substrate of neuraminidase and bind to the active site. It works by blocking the activity 
of viral neuraminidase preventing the enzyme from cleaving the cell receptors. 
Without the activity of neuraminidase, virus infection would be limited to only one 
round of replication, rarely enough to cause disease (Moscona, 2009).  
 
Figure 1.7 Mechanism of Action of Neuraminidase Inhibitors. Panel A shows the 
action of neuraminidase in the continued replication of virions in influenza infection. 
The replication is blocked by neuraminidase inhibitors (Panel B), which prevent them 
from being released from the surface of infected cells (Moscona, 2005). 
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 The ability of transition-state analogues of sialic acids in inhibiting the activity 
of influenza neuraminidase was first discovered in 1970s (Air, 2012), and the design 
of highly effective inhibitors became feasible when analysis of three dimensional 
structure of influenza neuraminidase disclosed the location and structure of catalytic 
site (Moscona, 2009). Neuraminidase inhibitors, zanamivir (Relenza) and oseltamivir 
(Tamiflu) have been approved by the US FDA in 1999 as antiviral drugs for influenza 
treatment and prophylaxis (Boltz et al., 2010, Moscona, 2009). Zanamivir mimics the 
natural substrate closely, fits into the active site’s pocket of neuraminidase and 
interacts with the protein in the most favorable way. Zanamivir is administered by oral 
inhalation which delivers the drug to the respiratory tract directly, while oseltamivir 
was developed through modifications to the sialic acids analogue framework 
(including the addition of lipophilic side chain) which allow the drug to be used orally 
(Moscona, 2009). Neuraminidase crystal structure in complex with zanamivir reveals 
the active site of neuraminidase with its important residues and their interaction with 
zanamivir (Figure 1.8). Asp151 is hydrogen bonded via one of the carboxyl oxygens 
to the secondary guanidinyl nitrogen of zanamivir, and the main-chain carbonyl 
oxygen interacts with one of the guanidino NH2 groups of the inhibitor. Arg152 also 
forms hydrogen bond with the carbonyl oxygen of the N-acetyl group of zanamivir. 
Val149 undergoes a Ctranslation of about 7.0 Å, as observed in the recent H5N1 NA 
structure. The side chain of Glu119 also adopts a different orientation, to point away 
from Glu227, interacting with Arg156 instead to accommodate the 4-guanidino group 
of zanamivir. Other conserved interactions among all other NAs include that of the 
carboxyl group of zanamivir with three conserved arginine residues, Arg118, Arg292, 
and Arg371, and that of the two terminal hydroxyl groups on the glycerol side chain 
on the C-6 position with the carboxylate of Glu276 (Xu et al., 2008). 
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Figure 1.8 Neuraminidase crystal structure in complex with zanamivir (PDB ID: 3B7E) 
(Xu et al., 2008).  
 
1.3  Computational Methods for Drug Discovery 
 The advanced technologies in the field of molecular biology, such as high-
throughput protein purification, crystallography and nuclear magnetic resonance 
spectroscopy techniques have contributed greatly to the increase of structural data of 
proteins and protein-ligand complexes (Meng et al., 2011). These structural discovery 
also allow the computational methodologies to become a crucial components for drug 
discovery and development strategies, from hit identification to lead optimization, and 
approaches such as ligand- or structure based virtual screening techniques (Kitchen et 
al., 2004). Compared with traditional experimental high-throughput screening (HTS) 
which has been applied to generate and screen large compound libraries, virtual 
screening is a more direct and rational drug discovery approach and has the advantage 
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of faster, more economical and effective screening  (Moitessier et al., 2008, Meng et 
al., 2011). 
 Virtual screening can be classified into ligand-based and structure-based 
method. Ligand-based methods, such as pharmacophore modelling and quantitative 
structure activity relationship (QSAR) methods, can be employed when a set of active 
ligand molecules is known and no or little structural information is available for targets. 
As to structure-based drug design, molecular docking is the most common method 
which has been widely used ever since the early 1980s (Meng et al., 2011). It remains 
a field of vigorous research, having become a useful tool in drug discovery efforts, and 
primary component in many drug discovery program (Sousa et al., 2006). Molecular 
docking, which is usually performed between a small molecule and a target 
macromolecule, is often referred to as ligand-protein docking. This method allows us 
to characterize the behaviour of small molecules (ligands) in the binding site of a target 
(protein, DNA, or RNA macromolecules) as well as to elucidate fundamental 
biochemical processes, to predict molecular recognition, both structurally, finding 
likely binding modes, and to predict binding affinity (Morris and Lim-Wilby, 2008, 
Meng et al., 2011). Molecular docking has a wide variety of uses and applications in 
drug discovery, including structure–activity studies, lead optimization, finding 
potential leads by virtual screening, providing binding hypotheses to facilitate 
predictions for mutagenesis studies, assisting x-ray crystallography in the fitting of 
substrates and inhibitors to electron density, chemical mechanism studies, and 
combinatorial library design. Virtual screening on the basis of molecular descriptors 
and physicochemical properties of (in)active ligands has great usefulness in finding 
hits and leads through library enrichment for screening (Morris and Lim-Wilby, 2008, 
Pozzan, 2006).  
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 The docking process involved two basic steps: prediction of the ligand 
conformation as well as its position and orientation within the site and assessment of 
binding affinity. Docking can be achieved through two interrelated steps; first by 
sampling conformations of the ligand in the active site of the protein; then ranking 
these conformations via a scoring function and thus give the prediction of the ligand-
receptor complex structure (Meng et al., 2011). There are various docking programs, 
such as AutoDock, DOCK, GOLD, ZDOCK, M-ZDOCK, MS DOCK, FLEXX, 
Surflex, MCDOCK, and others, based on specific search algorithm (Dias and de 
Azevedo Jr, 2008).  
 AutoDock is one of the most popular docking programs developed to provide 
an automated procedure for predicting the interaction of ligand with biomolecular 
targets (Morris et al., 2002, Sousa et al., 2006). All docking methods require a scoring 
function to rank the various candidate binding modes, and a search method to explore 
the state variables. Scoring functions can be empirical, force field based, or knowledge 
based, whereas search methods fall into two major categories: systematic and 
stochastic. Systematic search methods sample the search space at predefined intervals, 
and are deterministic. Stochastic search methods iteratively make random changes to 
the state variables until a user-defined termination criterion is met, so the outcome of 
the search varies. Search methods can also be classified by how broadly they explore 
the search space, as either local or global. Local search methods tend to find the nearest 
or local minimum energy to the current conformation, whereas global methods search 
for the best or global minimum energy within the defined search space. Hybrid global–
local search methods have been shown to perform even better than global methods 
alone, being more efficient and able to find lower energies. In AutoDock 4, for 
example, there are choices of two local search methods (Solis and Wets and Pattern 
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Search); two global search methods: Monte Carlo (MC) simulated annealing (SA) and 
the genetic algorithm (GA); and one hybrid global–local search method, the 
Lamarckian GA (LGA) (Morris and Lim-Wilby, 2008, Sousa et al., 2006).  
 
Scheme 1.2 Typical docking workflow. This flowchart shows the key steps common 
to all docking protocols. The 3D structures for the target macromolecule and the small 
molecule must first be chosen, and then each structure must be prepared in accordance 
with the requirements of the docking method being used. Following the docking, the 
results must be analyzed, selecting the binding modes with the best scores (Morris and 
Lim-Wilby, 2008). 
 
 AutoDock 4.2 uses a semi empirical free energy force field to evaluate 
conformation during docking simulations. The force field was parameterized using a 
large number of protein-inhibitor complexes for which both structure and inhibition 
constant, or Ki are known. 
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Figure 1.9 Mechanism of ligand interactions in the receptor binding site (Morris et al., 
2010) 
 The force field evaluates the binding in two steps.  The ligand and protein start 
in an unbound conformation. In the first step, the intramolecular energetics are 
estimated for the transition from these unbound states to the conformation of the ligand 
and protein in the bound state. The second step then evaluates the intermolecular 
energetics of combining the ligand and protein in their bound conformation (Figure 
1.9). The force field includes six pair-wise evaluation (V) and an estimate of the 
conformational entropy lost upon binding (Sconf):  
 
         Equation 1 
where L refers to the ‘ligand’ and P refers to the ‘protein’ in a ligand-protein docking 
calculation. Each of the pair-wise energetic terms includes evaluations for 
dispersion/repulsion, hydrogen bonding, electrostatics, and desolvation: 
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Equation 2 
(Morris et al., 2010) 
 Autodock is distributed with a GUI called AutodockTools (ADT; 
http://mgltools.scripps.edu). ADT is a part of MGLTools and built on the Python 
Molecular Viewer (PMV), it helps to prepare the ligand and receptor input files, and 
to set up the Autogrid and Autodock calculations. The key stages in docking are: 1) 
target selection and preparation, 2) ligand selection and preparation, 3) docking setup, 
and 4) evaluating docking results (Morris and Lim-Wilby, 2008). 
1.4 Enzyme Kinetics 
1.4.1 Maximum Velocity (Vmax) and Michaelis-Menten Constant (Km) 
 In vitro characterization of enzyme studies and substrate metabolism involves 
determination of qualitative profiles and quantitative parameters. Quantitative 
parameters generally include the estimation of kinetic parameters, such as maximum 
velocity (Vmax) and Michaelis-Menten constant (Km). Enyzme inhibition studies are 
conducted to characterize the type of inhibition process (i.e., competitive, 
uncompetitive, or noncompetitive) and to determine the inhibition constant (Ki) 
(Kakkar et al., 1999). 
 Kinetic study explains the rate of reaction, how fast an enzyme converts 
substrate to form product, which is also known as velocity. To determine velocity, 
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product (or substrate) concentration and time have to be measured. Velocity is the 
slope of a plot of product (or substrate) concentration against time (Figure 1.12) 
(Gilbert, 2000). 
 
Figure 1.10 Velocity of product formation or substrate disappearance is defined as the 
change in product concentration per unit time. Velocity is the slope of a plot of product 
concentration against time (Gilbert, 2000). 
 The Michaelis-Menten constant, Km, can be described as the equilibrium 
constant of the reversible combination of an enzyme with its substrate. It takes the state 
where a substrate S binds reversibly to an enzyme E to form an enzyme-substrate 
complex ES, which reacts irreversibly to generate a product P and also regenerates free 
enzyme E. This system can be represented as follows:  
    Equation 3 
The Michaelis-Menten equation for this system is:  
                                      Equation 4  
